|Post IPO Valuation|
|Description||A private biopharmaceutical company|
|Partial Close, 3/2010 ||$19.2M|
|Partial Close, 1/2011 ||$11.7M|
|Partial Close, 5/2012 ||$7.05M|
|Venture Round, 8/2012 ||$50M|
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs.
Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.